PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

Julia E Douglas, Suyu Liu, Junsheng Ma, Robert A Wolff, Shubham Pant, Anirban Maitra, Eric P Tamm, Priya Bhosale, Matthew H G Katz, Gauri R Varadhachary, Eugene J Koay, Julia E Douglas, Suyu Liu, Junsheng Ma, Robert A Wolff, Shubham Pant, Anirban Maitra, Eric P Tamm, Priya Bhosale, Matthew H G Katz, Gauri R Varadhachary, Eugene J Koay

Abstract

Background: Personalized and effective treatments for pancreatic ductal adenocarcinoma (PDAC) continue to remain elusive. Novel clinical trial designs that enable continual and rapid evaluation of novel therapeutics are needed. Here, we describe a platform clinical trial to address this unmet need.

Methods: This is a phase II study using a Bayesian platform design to evaluate multiple experimental arms against a control arm in patients with PDAC. We first separate patients into three clinical stage groups of localized PDAC (resectable, borderline resectable, and locally advanced disease), and further divide each stage group based on treatment history (treatment naïve or previously treated). The clinical stage and treatment history therefore define 6 different cohorts, and each cohort has one control arm but may have one or more experimental arms running simultaneously. Within each cohort, adaptive randomization rules are applied and patients will be randomized to either an experimental arm or the control arm accordingly. The experimental arm(s) of each cohort are only compared to the applicable cohort specific control arm. Experimental arms may be added independently to one or more cohorts during the study. Multiple correlative studies for tissue, blood, and imaging are also incorporated.

Discussion: To date, PDAC has been treated as a single disease, despite knowledge that there is substantial heterogeneity in disease presentation and biology. It is recognized that the current approach of single arm phase II trials and traditional phase III randomized studies are not well-suited for more personalized treatment strategies in PDAC. The PIONEER Panc platform clinical trial is designed to overcome these challenges and help advance our treatment strategies for this deadly disease.

Trial registration: This study is approved by the Institutional Review Board (IRB) of MD Anderson Cancer Center, IRB-approved protocol 2020-0075. The PIONEER trial is registered at the US National Institutes of Health (ClinicalTrials.gov) NCT04481204 .

Keywords: Borderline resectable; FOLFIRINOX; Gemcitabine/nab-paclitaxel; Locally advanced; PIONEER; Pancreatic cancer; Pancreatic ductal adenocarcinoma (PDAC); Phase II; Randomized platform trial; Resectable.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Trial Overview
Fig. 2
Fig. 2
Summary of control arms for platform trial
Fig. 3
Fig. 3
Trial schema and hypothetical randomization to the control and experimental arms
Fig. 4
Fig. 4
Disease Status Criteria
Fig. 5
Fig. 5
Eligibility and Ineligibility Criteria
Fig. 6
Fig. 6
Calendar of Testing and Observation (Resectable)

References

    1. Pisters PW, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20(10):2537–2544. doi: 10.1200/JCO.2002.11.064.
    1. Ashman JB, et al. Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. J Gastrointest Oncol. 2013;4(4):352–360.
    1. Versteijne E, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773. doi: 10.1200/JCO.19.02274.
    1. Yuan Y, et al. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016;22(17):4291–4301. doi: 10.1158/1078-0432.CCR-16-0592.
    1. Hahn SA, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95(3):214–221. doi: 10.1093/jnci/95.3.214.
    1. Almeida RR, et al. Advances in pancreatic CT imaging. Am J Roentgenol. 2018;211(1):52–66. doi: 10.2214/AJR.17.18665.
    1. Schueller G, et al. Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. Radiology. 2006;241(2):441–448. doi: 10.1148/radiol.2412051107.
    1. Wang S-L, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China. J Clin Oncol. 2020;38(31):3604–3614. doi: 10.1200/JCO.20.01024.
    1. Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. doi: 10.1056/NEJMoa1308573.
    1. Katz MHG, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17(1):505. doi: 10.1186/s12885-017-3441-z.
    1. Bernard V, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(1):108–118.e4. doi: 10.1053/j.gastro.2018.09.022.
    1. Koay EJ, et al. A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2018;24(23):5883–5894. doi: 10.1158/1078-0432.CCR-17-3668.
    1. Koay EJ, et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014;124(4):1525–1536. doi: 10.1172/JCI73455.
    1. Amer AM, et al. Imaging-based biomarkers: changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018;124(8):1701–1709. doi: 10.1002/cncr.31251.
    1. Cloyd JM, et al. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointest Surg. 2017;21(1):164–174. doi: 10.1007/s11605-016-3265-1.
    1. Krishnan S, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755–765. doi: 10.1016/j.ijrobp.2015.12.003.
    1. Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc: Ser C: Appl Stat. 2015;64(3):507–523. doi: 10.1111/rssc.12089.
    1. Yuan Y, et al. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016;35(22):3892–3906. doi: 10.1002/sim.6971.
    1. Pancreatic Cancer Action, N. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer. 2024. Available from: .

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する